Can definitive radiotherapy targeting the full ‘triangle’ space improve local disease control in patients with inoperable pancreatic cancer?

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...

Revolution Medicines announced at the AACR meeting in San Diego that its drug daraxonrasib showed strong efficacy in patients ...

Based on positive phase 3 trial results, a New Drug Application will be submitted to the Food and Drug Administration for daraxonrasib.

Individuals with a family history, among other factors, may have premalignant or early-stage pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) screening was effective for early ...

The annual Prospectors & Developers Association of Canada (PDAC) convention is returning this year from March 3 to 6, and it comes as countries around the world take steps to secure supply of key ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using ...

The annual Prospectors & Developers Association of Canada (PDAC) convention is returning this year from March 1 to 4, and it comes at a significant time for the global resource sector. Precious metals ...